Key statistics
On Wednesday, Invivyd Inc (IVVD:NMQ) closed at 0.9014, 11.06% above the 52 week low of 0.8116 set on Sep 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.90 |
---|---|
High | 0.9598 |
Low | 0.8919 |
Bid | 0.89 |
Offer | 0.9455 |
Previous close | 0.9065 |
Average volume | 283.91k |
---|---|
Shares outstanding | 119.44m |
Free float | 97.74m |
P/E (TTM) | -- |
Market cap | 108.27m USD |
EPS (TTM) | -1.80 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 21:00 BST.
More ▼
Announcements
- Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
- Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
- Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
- Invivyd to Participate in Upcoming Investor Conferences
- Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
- Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
- Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
- Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
- Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
More ▼